Moderna, Inc. (MRNA) Friday said the UK Court of Appeal has ruled that Moderna's EP'949 patent is valid and infringed by Pfizer/ BioNTech.
This decision upholds the High Court's initial ruling in July 2024 that the EP'949 patent was valid and infringed by Pfizer/ BioNTech's COVID-19 vaccine, Comirnati.
European patent EP'949 covers chemically modified mRNA, one of Moderna's core technologies used in the development of mRNA-based drugs.
In 2022, Moderna had sued Pfizer and BioNTech for patent infringement related to their COVID-19 vaccines, alleging they copied Moderna's mRNA technology.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.